Analyst Thomas Shrader of BTIG maintained a Buy rating on Novavax, retaining the price target of $19.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Shrader has given his Buy rating due to a combination of factors surrounding Novavax’s recent developments and strategic positioning. The approval of the Nuvaxoid vaccine for the 2025-2026 period, alongside the recognition of its six-month refrigerated shelf-life, enhances its attractiveness to distributors. This approval, occurring simultaneously with mRNA updates, signifies a positive acknowledgment of Novavax’s vaccine in the competitive landscape.
Additionally, the potential for large government contracts to replace mRNA vaccines could provide significant opportunities for Novavax, especially if they can integrate their internal flu vaccine development into these grants. The company’s ongoing efforts to partner its seasonal flu vaccine and the promising results from recent trials further bolster its prospects. Moreover, the ability of Nuvaxoid to offer protection with fewer short-term side effects compared to mRNA vaccines could drive sales if this advantage is widely recognized. These elements, combined with positive pipeline updates and strategic commercial partnerships, underpin Shrader’s optimistic outlook on Novavax’s stock.
In another report released on August 28, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $10.00 price target.